Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,138.80
(
0.00%
)
US TECH 100
26,348.80
(
0.18%
)
Dow Jones
49,141.93
(
0.00%
)
Brent Oil
108.11
(
3.54%
)
Bitcoin
77,149.62
(
1.05%
)
News Focus
News Focus
Post# of 257458
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122898
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 225327

Monday, 07/15/2019 5:14:08 PM

Monday, July 15, 2019 5:14:08 PM

Post# of 257458
ABUS reports phase-1b HBV data for AB-506:

https://finance.yahoo.com/news/arbutus-announces-preliminary-phase-1a-200500198.html

Mean HBV DNA and HBV RNA decreases at Day 28 (end of treatment) ranged from -2.0 log (160mg dose) to -2.8 log (400mg dose) and -2.4 log (for both doses), respectively…

These log-reduction-in viral-load numbers seem a little low for 28 days of treatment.

ABUS’ AB-506 works by the same MoA as ENTA’s EDP-514 (#msg-149794330). ASMB has one too (#msg-148672065).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now